Across four in-depth sessions the latest improvements pushing the industry forward will be addressed: from stability & clinical manufacturing, RNA computational design approaches, through to case studies & recent developments in [….]
Cerecor Rebrands to Avalo Therapeutics. Eighteen months after completing its merger with Aevi Genomic Medicine, Cerecor is rebranding to Avalo Therapeutics. The rebranding to Avalo reflects the company’s aims to focus on three core indications, on immunology, immuno-oncology, and rare genetic diseases.
AavantiBio and Catalent Announce Partnership to Support Development and Manufacturing of Gene Therapies for Rare Genetic Diseases
Partnership to advance AavantiBio’s diversified gene therapy pipeline, including the Company’s lead program in Friedreich’s Ataxia (FA)